During 72 weeks of treatment, people taking tirzepatide at doses of 5, 10, or 15 mg lost an average of 15.0%, 19.5%, and 20.9%, respectively, compared with just 3.1% in people taking a placebo
Many users find that metabolic benefits persist for several weeks after discontinuing treatment, suggesting lasting improvements in cellular function
The injectable route through compounded tirzepatide is especially valuable for this group
People who do not eat meat or dairy products, women who are pregnant or breastfeeding, and people with certain genetic conditions may have a hard time getting vitamin B from their diets
In-Vitro Research Only Products are supplied exclusively as laboratory materials for legitimate in-vitro research, analytical testing, method development, or comparable non-clinical work conducted outside a living human or animal body in an appropriately controlled research environment
Get the blood test first